Financing channel feed – Endpoints News

Financing channel feed

Grail CSO Vikram Bajaj jumps to VC firm Foresite, takes lead on personalized meds

8 years ago

Atlas-incubated Kymera leaps out of stealth mode, joins the hunt for game-changing protein degradation drugs

8 years ago

John Hood bags $90M for his quest to get fedratinib OK’d by FDA and catapult into the market

8 years ago

Ablynx IPO raises $200M for its nanobody platform effort

8 years ago

Eyeing a big heart failure market, scPharmaceuticals aims for $100M IPO

8 years ago

Genmab vets at low-profile Y-mAbs steer two MSK cancer drugs to the FDA after landing $50M from HBM

8 years ago

Going all in: Biogen commits an extra $500M to Alzheimer’s blockbuster hopeful aducanumab

8 years ago

With a pipeline from Gerngross’ Adimab, Arsanis hunts a $58M IPO for antibody development work

8 years ago

Eyeing an IPO, ADC Therapeutics fuels pivotal cancer trials with a $200M mega-round backed by AstraZeneca

8 years ago

Peer Review: Eyeing a $350M venture fund, Nextech recruits Third Rock’s Jakob Loven for the team

8 years ago

Google’s GV and allies double down on Forty Seven with their second $75M round

8 years ago

Pfizer, NEA back Cydan II's plans to launch a fresh slate of biotech startups focused on rare genetic diseases

8 years ago

Armed with $42.5M, Gemini embraces the Goldilocks strategy in bringing precision med to AMD

8 years ago

OptiNose joins the biotech IPO fiesta, raises $120M in upsized offering

8 years ago

Four years after it imploded at Sanofi, John Hood is resurrecting the myelofibrosis drug fedratinib

8 years ago

Bain, RA back InflaRx’s $55M round after early study produces promising results

8 years ago

Medicxi kickstarts a new cancer drug developer with $19M launch round

8 years ago

Shooting for PhIII, Spero tees up a new lead antibiotic in-licensed cheap as it lines up $86M IPO

8 years ago

Deerfield commits $50M-plus to translational drug R&D at the Broad

8 years ago

Abbas Hussain swings from top GSK pharma post to powerhouse Chinese private equity player C-Bridge

8 years ago

Third Rock-backed Allena looks to springboard a $92M IPO off of a failed PhIIb

8 years ago

Third Rock, SV bankroll another PhI/II for a new, improved and jab-free wet AMD drug

8 years ago

Facebook billionaires Peter Thiel and Sean Parker backing a stealth immunotherapy biotech — report

8 years ago

Armed with a $47M round, Gates-backed Visterra aims at a PhIIb flu drug study

8 years ago

First page Previous page 135 136 137138139 140 141 Next page Last page